L. Renda

446 total citations
9 papers, 203 citations indexed

About

L. Renda is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, L. Renda has authored 9 papers receiving a total of 203 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 3 papers in Dermatology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in L. Renda's work include Psoriasis: Treatment and Pathogenesis (8 papers), Autoimmune Bullous Skin Diseases (2 papers) and Dermatology and Skin Diseases (2 papers). L. Renda is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (8 papers), Autoimmune Bullous Skin Diseases (2 papers) and Dermatology and Skin Diseases (2 papers). L. Renda collaborates with scholars based in United States, United Kingdom and Japan. L. Renda's co-authors include Andrew Blauvelt, Melinda Gooderham, C.E.M. Griffiths, Russel Burge, Gaia Gallo, Kim Papp, Noah Agada, Orin M. Goldblum, Renata Gontijo Lima and Lyn Guenther and has published in prestigious journals such as Journal of Investigative Dermatology, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

L. Renda

9 papers receiving 200 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Renda United States	5	181	107	38	34	34	9	203
Megan Mosca United States	8	181 1.0×	117 1.1×	36 0.9×	44 1.3×	14 0.4×	22	241
Murali Sundaram United States	4	150 0.8×	85 0.8×	52 1.4×	29 0.9×	24 0.7×	6	202
Federico Pirrò Italy	8	157 0.9×	114 1.1×	44 1.2×	37 1.1×	11 0.3×	11	205
Stephanie Mehlis United States	6	253 1.4×	151 1.4×	49 1.3×	53 1.6×	20 0.6×	14	310
Maximilian Reinhardt Germany	10	184 1.0×	136 1.3×	115 3.0×	78 2.3×	25 0.7×	18	301
Renata Gontijo Lima United States	5	168 0.9×	255 2.4×	60 1.6×	31 0.9×	13 0.4×	8	358
Abby Jacobson United States	12	350 1.9×	253 2.4×	53 1.4×	64 1.9×	48 1.4×	52	386
Jingzhi Jiang United States	7	309 1.7×	279 2.6×	48 1.3×	41 1.2×	28 0.8×	10	399
Hany Elmaraghy United States	9	261 1.4×	315 2.9×	66 1.7×	62 1.8×	22 0.6×	30	419
Lorne Albrecht Canada	7	94 0.5×	102 1.0×	20 0.5×	15 0.4×	27 0.8×	16	161

Countries citing papers authored by L. Renda

Since Specialization

Citations

This map shows the geographic impact of L. Renda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Renda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Renda more than expected).

Fields of papers citing papers by L. Renda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Renda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Renda. The network helps show where L. Renda may publish in the future.

Co-authorship network of co-authors of L. Renda

This figure shows the co-authorship network connecting the top 25 collaborators of L. Renda. A scholar is included among the top collaborators of L. Renda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Renda. L. Renda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Blauvelt, Andrew, C. Leonardi, Boni E. Elewski, et al.. (2020). A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. British Journal of Dermatology. 184(6). 1047–1058. 73 indexed citations

Korman, Neil J., William N. Malatestinic, Orin M. Goldblum, et al.. (2020). Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient’s perspective. Journal of Dermatological Treatment. 33(2). 733–739. 11 indexed citations

Blauvelt, Andrew, Andreas Pinter, Yayoi Tada, et al.. (2020). LB940 Ixekizumab versus guselkumab: 24-week clinical responses and 4-week gene expression data. Journal of Investigative Dermatology. 140(7). B9–B9. 2 indexed citations

Blauvelt, Andrew, Kim Papp, A.B. Gottlieb, et al.. (2020). A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis. British Journal of Dermatology. 182(6). 1 indexed citations

Blauvelt, Andrew, Catherine Maari, Alice B. Gottlieb, et al.. (2020). 14152 Patient-reported outcomes in a head-to-head, randomized, double-blinded clinical trial of ixekizumab and guselkumab in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology. 83(6). AB19–AB19. 4 indexed citations

Shrom, David, et al.. (2019). Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey. Dermatology and Therapy. 9(4). 785–797. 33 indexed citations

Goldblum, Orin M., L. Renda, Noah Agada, et al.. (2019). Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis. Dermatology and Therapy. 10(1). 99–106. 23 indexed citations

Amato, Dante, et al.. (2019). 592 Impact of scalp psoriasis on quality of life measurements at baseline and following treatment with ixekizumab. Journal of Investigative Dermatology. 139(5). S102–S102. 2 indexed citations

Armstrong, April W., C. Paul, L. Puig, et al.. (2019). Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. Dermatology and Therapy. 10(1). 133–150. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact